Despite the failure of Eli Lilly’s anti-amyloid antibody solanezumab in its latest phase III trial for Alzheimer disease, a bulging pipeline of amyloid-modulating candidates and novel clinical trial strategies still hold promise.

Nature Reviews Drug Discovery 16, 3–5 (2017) doi:10.1038/nrd.2016.281